Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Barry Manilow to have surgery for early-stage lung cancer and postpones January concerts - 2Vote in favor of Your Number one kind of pie
- 3Elite Execution Wall televisions for Film Darlings
- 4Find Successful Magnificence Items for Sparkling Skin
- 5Astonishing Deserts All over The Planet You Really want To Visit
- From Amateur to Master: My Involvement in Photography
- People who talk with their hands seem more clear and persuasive – new research
- Top 15 Web-based Entertainment Stages for Individual Marking
- A Colombian city swaps iconic horse buggies for electric carriages amid animal welfare concerns
- Exhaustive Experiences into Prudent Senior Living in the UK
- Here's how 'Bridgerton' fans can watch the first episode of Season 4 before its Netflix release later this month
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- Without evidence, CDC changes messaging on vaccines and autism
- Israel’s mixed messaging on Christmas draws controversy
